Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00230971
Other study ID # 3074A1-315
Secondary ID
Status Completed
Phase Phase 4
First received September 30, 2005
Last updated February 20, 2013
Start date October 2005
Est. completion date September 2008

Study information

Verified date February 2013
Source Wyeth is now a wholly owned subsidiary of Pfizer
Contact n/a
Is FDA regulated No
Health authority European Union: European Medicines AgencyAustralia: Human Research Ethics CommitteeHong Kong: Joint CUHK-NTEC Clinical Research Ethics CommitteeIndia: Institutional Review BoardRepublic of the Philippines: Ethics CommitteeTaiwan: Institutional Review BoardDenmark: Ethics CommitteeFinland: National Advisory Board on Health Care EthicsFrance: Institutional Ethical CommitteeGermany: Ethics CommissionGreece: Ethics CommitteeItaly: Ethics CommitteeSaudi Arabia: Ethics CommitteeSouth Africa: Human Research Ethics CommitteeSpain: Ethics CommitteeSwitzerland: EthikkommissionTurkey: Ministry of HealthUnited Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolution or stability of the adverse event(s).


Recruitment information / eligibility

Status Completed
Enrollment 473
Est. completion date September 2008
Est. primary completion date September 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Clinical diagnosis of complicated intra-abdominal infection that requires surgery within 24 hours.

- Fever plus other symptoms such as nausea, vomiting, abdominal pain.

Exclusion Criteria:

- Cancer

- Medicines that suppress the immune system

- Dialysis

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
tigecycline
every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
ceftriaxone plus metronidazole
Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Countries where clinical trial is conducted

Australia,  China,  Denmark,  Finland,  France,  Germany,  Greece,  Hong Kong,  India,  Italy,  Philippines,  Portugal,  Saudi Arabia,  South Africa,  Spain,  Switzerland,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) Visit CE population were those who completed TOC assessment of cure or failure (but not indeterminate) or, in case of premature discontinuation due to lack of efficacy, had completed end of treatment assessment such that assessment of clinical response could be made. Clinical response was assigned by investigator per protocol-specified guidelines and defined as: test article and initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. TOC performed 10-28 days after last dose of study drug. up to 6 weeks No
Secondary Number of Microbiologically Evaluable (ME) Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit ME population were subjects who were clinically evaluable and had baseline culture with at least 1 identified isolate that was susceptible to study drug and comparator. The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection. up to 6 weeks No
Secondary Number of Microbiologically Evaluable (ME) Patients by Microbiological Response at Test-of-Cure (TOC) Visit Microbiological response was assessed at patient level was the combined responses for all baseline isolates identified in intra-abdominal and blood cultures. Eradication=baseline isolate not recovered from primary infection site/blood; Presumed Eradication=No sample for culture, clinical response was cure; Persistence=baseline isolate recovered from primary infection site/blood; Presumed Persistence=No sample available for culture, clinical response was failure; Superinfection=culture from primary infection site with new isolate not identified at baseline, clinical response was failure. up to 6 weeks No
Secondary Number of Days of Inpatient Healthcare Resource Utilization on or Before Test-of-Cure Healthcare resource utilization assessment included days of overall inpatient hospitalization, days of primary inpatient hospitalization, days of Intensive Care Unit (ICU) treatment and days of non-ICU inpatient hospitalization up to 6 weeks No
See also
  Status Clinical Trial Phase
Completed NCT04529980 - Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis N/A
Withdrawn NCT03528343 - Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy Phase 1/Phase 2
Recruiting NCT03522233 - Pediatric Appendicitis Risk Calculator (pARC) in Children With Appendix Ultrasounds
Recruiting NCT03380793 - A Trial to Assess the Efficacy and Safety of Morinidazole in Patients With Appendicitis Phase 4
Recruiting NCT02108340 - Comparative Study of Microwave Radiometry and Ultrasonography for the Diagnosis of Acute Appendicitis N/A
Terminated NCT02029781 - The Laparoscopic Appendicitis Score; a Multicenter Validation Study N/A
Completed NCT01356641 - Antibiotic Treatment Alone for Acute Simple Appendicitis in Children N/A
Completed NCT01515293 - Single Incision Versus Conventional Laparoscopic Appendectomy Phase 3
Terminated NCT00971438 - Structured Management of Patients With Suspicion of Appendicitis Using a Clinical Score and Selective Imaging N/A
Completed NCT00913380 - Diagnosis of Acute Appendicitis: Low-dose Computed Tomography (CT) Versus Standard-dose CT Phase 3
Completed NCT00530998 - Minimally Invasive Surgery: Using Natural Orfices
Completed NCT00616616 - Single Incision Laparoscopy N/A
Completed NCT00195351 - Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection Phase 4
Completed NCT02916134 - Conservative Versus Operative ManageMent of Acute Uncomplicated Appendicitis N/A
Completed NCT04614649 - Right Iliac Fossa Treatment-Turkey Audit
Completed NCT04365491 - European Society for Trauma and Emergency Surgery (ESTES) Cohort Study Snapshot Audit 2020 - Acute Appendicitis
Completed NCT03770897 - Laparoscopic Appendectomy Performed by Junior SUrgeonS: Impact of 3D Visualization on Surgical Outcome N/A
Completed NCT02507674 - Point of Care 3D Ultrasound for Pediatric Appendicitis: a Pilot Study
Active, not recruiting NCT01718275 - Non-operative Management of Early Appendicitis in Children
Terminated NCT01575028 - Transversus Abdominis Plane (TAP) Versus Local Anesthetic for Lap Appendectomies Phase 2